The Eastern Company reported a significant increase in net income for the third quarter of 2026, reaching $3.4 million compared to $0.6 million in the prior year period, driven by a 35% increase in net sales. For the nine-month period, net income was bolstered by a $6.5 million bargain purchase gain from an acquisition, resulting in total net income of $9.7 million.
SANUWAVE Health reported Q3 2026 revenue of $8.6 million, a 24% decrease year-over-year, primarily driven by a significant drop in Ultramist system sales. The company posted a net loss of $1.4 million for the quarter, compared to net income of $9.7 million in the prior year, which had benefited from one-time gains. Management attributed the performance to market uncertainty surrounding proposed CMS rule changes affecting wound care reimbursement.
Term
Q3 2026
“Q3 was very much the story of the CMS proposed rule. This affected Sanuwave in multiple ways. The proposal to maintain skin substitute pricing at 2026 levels for 2027 caused a number of mobile wound care practitioners, particularly those providing rural home care, to exit some or all of their operations.”
Cumberland Pharmaceuticals reported Q3 2026 financial results, its first full quarter as a development-focused company following the $100 million divestiture of its commercial brands to Apotex Health. The company announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD) following a successful Phase 2 trial.
Term
Q3 2026
“Our first full quarter as a development-focused company has reinforced the value of concentrating our efforts on our clinical pipeline. Our team and resources are now dedicated to developing new medicines for unmet medical needs. We have the financial strength and the expertise to pursue our new mission, as we work to create lasting value for patients and shareholders.”
Mercury Systems reported net revenues of $253.2 million for the first quarter ended October 2, 2026, a significant increase from $225.2 million in the prior year. The company achieved a net income of $13.1 million, rebounding from a net loss of $12.5 million in the same period last year, driven by improved gross margins and lower operating expenses.
Suja Life, Inc. completed its IPO on May 8, 2026, raising net proceeds of $173.6 million used primarily for debt repayment and incentive unit settlements. For the nine months ended September 28, 2026, net sales grew to $267.3 million from $236.5 million year-over-year, though the company reported a net loss of $28.4 million driven by transaction costs and debt extinguishment.
Sunrise Realty Trust reported net income of $2.88 million for the quarter ended September 30, 2026, a decrease from $4.05 million in the prior year period, primarily due to higher interest expenses and merger-related costs. Total assets decreased to $285.4 million from $310.2 million at year-end 2025, while the company maintained a quarterly dividend of $0.30 per share.
Spire Global reported revenue of $18.0 million for the third quarter of 2026, an increase from $12.7 million in the prior year period. Despite the quarterly growth, the company recorded a net loss for the nine months ended September 30, 2026, contributing to an accumulated deficit of $553.4 million.
For the nine months ended September 30, 2026, Evolv Technologies reported total revenue of $137.4 million, a 28% increase compared to the same period in 2025. The company reduced its net loss to $29.9 million from $44.0 million year-over-year, driven by improved gross margins and a significant increase in product revenue.
For the nine months ended September 30, 2026, West Bay BDC LLC reported total investment income of $38.18 million and net investment income of $19.71 million, a significant increase from the prior year. Total members' capital grew to $319.81 million as of September 30, 2026, driven by common unit issuances and operational performance, while net asset value per unit increased to $17.57.
For the nine months ended September 30, 2026, Phillip Street BDC LLC reported total investment income of $67.6 million and net investment income of $38.3 million. Total members' capital increased to $572.1 million, with a net asset value per unit of $20.12, up from $19.83 at the end of 2025.
Elutia Inc. is focusing on the development of its next-generation biologic scaffolds, NXT-41 and NXT-41x, following the divestiture of its SimpliDerm and Orthobiologics businesses. The company is managing ongoing litigation related to its FiberCel and VBM product recalls while navigating capital requirements and Nasdaq compliance.
Silver Capital Holdings LLC reported a net decrease in net assets resulting from operations of $17.93 million for the nine months ended September 30, 2026, primarily driven by $37.98 million in net unrealized depreciation. Total investment income decreased significantly to $18.98 million from $44.22 million in the prior year period, while the company's net asset value per unit fell to $18.62 from $21.46 at year-end 2025.
The Eastern Company reported a 36% year-over-year increase in net sales to $75.0 million for the third quarter of 2026, driven by organic growth in truck mirror assemblies and the first full quarter of contributions from Sungear and Crown Precision. Net income from continuing operations rose significantly to $3.4 million, or $0.57 per diluted share, while the company's backlog grew 70% to $126.1 million. Management highlighted the benefits of restructuring initiatives and improved demand across aerospace, defense, and commercial transportation markets.
Term
Q3 2026
“The third quarter showed what Eastern can deliver when the benefits of our restructuring initiatives implemented over the past year are combined with improving demand.”
Ryan Schroeder, Eastern’s President and CEO
“Our job from here is execution: convert the backlog, protect our margins, and stay disciplined on capital, including acquisitions that complement our core strengths and enhance long-term value.”
Stellar V Capital Corp. reported a net income of $2.96 million for the nine months ended September 30, 2026, primarily driven by $4.24 million in interest earned on marketable securities held in the Trust Account. The company remains a shell entity with $160.97 million in Class A ordinary shares subject to possible redemption and is actively seeking a target for its initial business combination.
Dolphin Entertainment reported record quarterly revenue of $16.0 million for Q3 2026, an 8.3% year-over-year increase. The company achieved profitability with net income of $0.2 million and a 42.9% increase in Adjusted EBITDA to $1.6 million, driven by organic growth and improved operating leverage.
Term
Q3 2026
“Dolphin had an outstanding third quarter. Revenue for the quarter grew 8.3% year-over-year to $16.0 million, the highest quarterly revenue in Dolphin’s history, even including Q1 2024 when we reported $3.4 million from Blue Angels.”
Bill O’Dowd, CEO of Dolphin
“We reported net income of $0.2 million, compared to a net loss of $0.4 million a year ago, and adjusted EBITDA increased 42.9% to $1.6 million versus $1.1 million a year ago.”
For the nine months ended September 30, 2026, Goldman Sachs Private Middle Market Credit II LLC reported total investment income of $113.26 million and net investment income of $70.61 million. The company experienced significant net unrealized depreciation of $55.19 million across its investment portfolio, contributing to a net asset value per unit of $65.20 compared to $68.62 at the end of 2025.
U.S. GoldMining Inc. reported a significant increase in net loss to $14.3 million for the nine months ended September 30, 2026, compared to $5.0 million in the prior year, primarily driven by a surge in exploration expenses at the Whistler Project. The company remains in the exploration stage with no revenue, relying on equity financing including At-The-Market and registered direct offerings to fund its operations.
Netlist reported a significant increase in net sales to $105.1 million for the third quarter of 2026, driven by a $44.9 million license fee and strong product sales. The company achieved a net income of $85.4 million for the quarter, aided by a $44.0 million income tax benefit and a substantial increase in deferred revenue.
Resideo Technologies reported a net income of $22 million for the third quarter of 2026, a significant decrease from $156 million in the prior year period. The company completed the ADI Spin-Off during the period, resulting in a substantial reduction in total assets from $8.4 billion to $4.1 billion and a shift to a retained deficit of $1.4 billion.
Veradermics, Inc. is a clinical-stage biopharmaceutical company focused on developing VDPHL01 for pattern hair loss. As of November 5, 2026, the company had 42,195,472 shares of common stock outstanding and continues to incur substantial losses with no products yet approved for commercial sale.
Apollo Origination II (UL) Capital Trust reported total investment income of $44.87 million for the nine months ended September 30, 2026, compared to $34.44 million in the prior year period. Net asset value per share decreased slightly to $25.39 from $25.55 at year-end 2025, primarily driven by net change in unrealized losses on investments.
Gevo, Inc. reported a significant net loss of $172.5 million for the nine months ended September 30, 2026, primarily driven by a $135.8 million impairment of long-lived assets and a $40.3 million allowance for credit losses. Despite these charges, total revenues grew to $172.4 million compared to $115.2 million in the prior year period, and the company generated positive cash flow from operations of $12.0 million.
For the nine months ended September 30, 2026, Apollo Origination II (Levered) Capital Trust reported total investment income of $101.9 million and net investment income of $51.3 million. Total net assets grew to $835.9 million, driven by $105 million in net proceeds from common share issuances, despite a net change in unrealized losses of $12.4 million during the period.
T Series BDC LLC's Form 10-Q for the period ended September 30, 2026, details its financial performance and investment activity as a business development company. The filing highlights net investment income, changes in net assets from operations, and the current fair value of its private debt and equity portfolio.
PetMed Express reported a significant decline in net sales of 19.6% for the six months ended September 30, 2026, resulting in a net loss of $12.6 million. Management identified substantial doubt about the company's ability to continue as a going concern due to declining cash balances and ongoing operating losses, though they believe strategic cost reductions and marketing optimizations will alleviate these concerns.
Gossamer Bio reported Q3 2026 financial results, highlighting the submission of its first New Drug Application (NDA) to the FDA for seralutinib in PAH. The company also noted a structured private placement that provided $25 million upfront and could unlock an additional $125 million upon FDA acceptance of the NDA. Additionally, the company completed a 1-for-80 reverse stock split in September 2026 to regain Nasdaq compliance.
Term
Q3 2026
“Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH. Furthermore, FDA acceptance of the application in 2026 would, subject to other customary closing conditions, unlock up to approximately $125 million in additional committed capital to support our priorities, including preparations for a potential launch. We remain focused on supporting the FDA’s review and preparing for a potential commercial launch of seralutinib in 2027.”
Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer
ABVC BioPharma reported accrued research and development expenses of $1,741,083 as of September 30, 2026, primarily for manufacturing and process development. The company noted potential increases in future accruals due to the planned resumption of ophthalmology and CNS clinical trials.
Gossamer Bio reported total revenue of $64.6 million for the nine months ended September 30, 2026, compared to $34.7 million in the prior year, primarily driven by collaboration contracts. Despite the revenue growth, the company recorded a net loss of $77.8 million for the period, impacted by significant non-cash items including a $54.9 million remeasurement of warrant liability and a $43.8 million gain on debt extinguishment.
Autolus Therapeutics plc, a foreign private issuer voluntarily filing a Form 10-Q, reported 266,340,330 ordinary shares outstanding as of November 9, 2026. The filing highlights the commercialization of AUCATZYL for adult r/r B-ALL and notes a restructuring and workforce reduction plan initiated in April 2026.
Metropolitan Life Insurance Company reported total assets of $375.9 billion as of September 30, 2026, a decrease from $383.5 billion at year-end 2025. Stockholder's equity declined to $12.4 billion, primarily driven by an increase in accumulated other comprehensive loss, while the company continues to operate as a wholly-owned subsidiary of MetLife, Inc. under a reduced disclosure format.